Respiratory syncytial virus (RSV) is a virus that causes both upper and lower respiratory tract infections. Children under 1 year of age, individuals with underlying medical conditions (e.g. chronic cardiac and lung disease), the older population and immunocompromised people are more likely to experience serious disease requiring hospitalisation.
MVEC has recently updated its RSV reference page to include information on the administration of Arexvy, the only RSV vaccine available in Australia. This vaccine is registered for use in all adults aged 60 years and over and is specifically recommended for certain populations.